Key result
PAR1 antagonist SCH79797 boosts survival by ~79% in mice with lethal influenza, reducing lung inflammation.
Why the study?
Does PAR1 antagonism improve survival and reduce lung inflammation in mice infected with influenza A virus?
Does PAR1 antagonism improve survival and reduce lung inflammation in mice infected with influenza A virus?
Absolute Event Rate: 84% vs 47%
p-value: p=<0.05
PAR1 contributes to influenza A virus pathogenicity, suggesting PAR1 antagonism could be a potential therapeutic strategy for severe influenza.
PAR1 antagonism improves murine influenza survival; hypothesis-generating for human trials, should not yet change practice.
Influenza causes substantial morbidity and mortality, and highly pathogenic and drug-resistant strains are likely to emerge in the future. Protease-activated receptor 1 (PAR1) is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces. The role of PAR1 in pathogenesis of virus infections is unknown. Here, we demonstrate that PAR1 contributed to the deleterious inflammatory response after influenza virus infection in mice. Activating PAR1 by administering the agonist TFLLR-NH2 decreased survival and increased lung inflammation after influenza infection. Importantly, both administration of a PAR1 antagonist and PAR1 deficiency protected mice from infection with influenza A viruses (IAVs). Treatment with the PAR1 agonist did not alter survival of mice deficient in plasminogen (PLG), which suggests that PLG permits and/or interacts with a PAR1 function in this model. PAR1 antagonists are in human trials for other indications. Our findings suggest that PAR1 antagonism might be explored as a treatment for influenza, including that caused by highly pathogenic H5N1 and oseltamivir-resistant H1N1 viruses.
No takes yet. Share an insight, caveat, or question.
Khoufache et al. (2012) studied Influenza A virus infection. PAR1 antagonist (SCH79797) vs. Untreated control / vehicle was evaluated on Survival rate after lethal H1N1 infection (500 PFU) (p=<0.05). Administration of the PAR1 antagonist SCH79797 protected mice from lethal influenza A virus infection, increasing survival from 47% to 84% and reducing lung inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: